Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT1 | Q96EB6 | 16/20 | 1.00 |
| ▸ | SIRT2 | Q8IXJ6 | 5/20 | 0.85 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.85 |
| ▸ | RECQL | P46063 | 1/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1874310 | 0.92 | SIRT1 (1.00) | SIRT1SIRT2SIRT3RECQLALOX15 | |
| SCHEMBL1275557 | 0.92 | SIRT1 (1.00) | SIRT1SIRT2SIRT3RECQLALOX15 | |
| SCHEMBL1870769 | 0.92 | SIRT1 (1.00) | SIRT1SIRT2SIRT3RECQLALOX15 | |
| SCHEMBL8257650 | 0.91 | SIRT1 (1.00) | SIRT1SIRT2SIRT3RECQLALOX15 | |
| SCHEMBL1873844 | 0.91 | SIRT1 (1.00) | SIRT1SIRT2SIRT3RECQLALOX15 | |
| SCHEMBL13960995 | 0.91 | SIRT1 (0.83) | SIRT1SIRT2SIRT3RECQLALOX15 | |
| SCHEMBL8251110 | 0.91 | SIRT1 (1.00) | SIRT1SIRT2SIRT3RECQLALOX15 | |
| SCHEMBL3673946 | 0.88 | SIRT1 (0.78) | SIRT1SIRT2SIRT3ALOX15MEN1 | |
| SCHEMBL16266029 | 0.84 | SIRT1 (0.85) | SIRT1SIRT2SIRT3RECQL | |
| SCHEMBL3484381 | 0.80 | SIRT1 (1.00) | SIRT1SIRT2SIRT3RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140030295-A1 | Use of Sirt1 Activators or Inhibitors to Modulate an Immune Response | THE J. DAVID GLADSTONE INSTITUTES (US) | 2014-01-30 | — | — | US | claimed |
| US-20100330114-A1 | Use of SIRT1 Activators or Inhibitors to Modulate an Immune Response | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-12-30 | — | — | US | claimed |
| WO-2009099643-A1 | USE OF SIRT1 ACTIVATORS OR INHIBITORS TO MODULATE AN IMMUNE RESPONSE | THE J. DAVID GLADSTONE INSTITUTES (US) | 2009-08-13 | — | — | WO | claimed |
| EP-1677794-B1 | METHODS OF TREATING DISORDER | ELIXIR PHARMACEUTICALS INC (US) | 2014-12-03 | — | — | EP | disclosed |
| US-8748464-B2 | Use of SIRT1 activators or inhibitors to modulate an immune response | THE J. DAVID GLADSTONE INSTITUTES (US) | 2014-06-10 | — | — | US | disclosed |
| US-20140030295-A1 | Use of Sirt1 Activators or Inhibitors to Modulate an Immune Response | THE J. DAVID GLADSTONE INSTITUTES (US) | 2014-01-30 | — | — | US | disclosed |
| US-20100330114-A1 | Use of SIRT1 Activators or Inhibitors to Modulate an Immune Response | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-12-30 | — | — | US | disclosed |
| WO-2009099643-A1 | USE OF SIRT1 ACTIVATORS OR INHIBITORS TO MODULATE AN IMMUNE RESPONSE | THE J. DAVID GLADSTONE INSTITUTES (US) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100330114-A1 | Use of SIRT1 Activators or Inhibitors to Modulate an Immune Response | SIRT1, SIRT2, NFATC1 | SIRT1 1/4885SIRT2 2/4885SIRT3 5/4885 |
| US-20140030295-A1 | Use of Sirt1 Activators or Inhibitors to Modulate an Immune Response | SIRT1, SIRT2, NFATC1 | SIRT1 1/4885SIRT2 2/4885SIRT3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.